Apogee Therapeutics Inc. (NASDAQ:APGE) Given Consensus Rating of “Hold” by Brokerages

Apogee Therapeutics Inc. (NASDAQ:APGE) has been given a consensus rating of “Hold” by the twenty-one ratings firms that are covering the stock, Marketbeat reports. One investment analyst has rated the stock with a sell rating, fifteen have issued a hold rating, four have issued a buy rating and one has given a strong buy rating to the company. The average twelve-month price objective among brokers that have updated their coverage on the stock in the last year is $121.2547.

Several equities analysts have recently commented on APGE shares. Craig Hallum set a $135.11 target price on shares of Apogee Therapeutics and gave the stock a “hold” rating in a report on Monday. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Apogee Therapeutics in a research note on Monday, April 20th. UBS Group downgraded shares of Apogee Therapeutics from a “buy” rating to a “neutral” rating and lifted their price target for the company from $100.00 to $135.11 in a report on Tuesday. Guggenheim cut shares of Apogee Therapeutics from a “buy” rating to a “neutral” rating in a research note on Tuesday. Finally, Mizuho reissued a “neutral” rating and set a $135.00 price objective (up from $110.00) on shares of Apogee Therapeutics in a report on Wednesday.

Apogee Therapeutics News Roundup

Here are the key news stories impacting Apogee Therapeutics this week:

• Positive Sentiment: Apogee’s proposed sale to AbbVie for $135.11 per share continues to anchor the stock near deal value and provides clear upside support for investors. Article Title
• Neutral Sentiment: Stifel kept a hold rating and raised its price target to $135, signaling the shares are already trading close to fair value under the transaction terms. Article Title
• Neutral Sentiment: Mizuho downgraded APGE to hold but lifted its target to $135, reflecting limited additional upside beyond the deal price. Article Title
• Neutral Sentiment: Short-interest data showed no meaningful change in bearish positioning, offering little new signal for traders. Article Title
• Negative Sentiment: Insider sales by CEO Michael Henderson and insider Carl Dambkowski may add some pressure, even though both transactions were made under pre-arranged 10b5-1 plans. Article Title
• Negative Sentiment: A law firm launched an investigation into whether the proposed sale price and process were adequate, creating a legal overhang that could complicate the deal. Article Title

Insider Buying and Selling

In other Apogee Therapeutics news, CEO Michael Thomas Henderson sold 80,000 shares of the firm’s stock in a transaction that occurred on Monday, June 22nd. The stock was sold at an average price of $132.54, for a total transaction of $10,603,200.00. Following the completion of the transaction, the chief executive officer owned 1,015,987 shares in the company, valued at $134,658,916.98. This trade represents a 7.30% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Carl Dambkowski sold 26,400 shares of Apogee Therapeutics stock in a transaction that occurred on Monday, June 22nd. The stock was sold at an average price of $132.60, for a total value of $3,500,640.00. Following the completion of the sale, the insider directly owned 179,248 shares in the company, valued at approximately $23,768,284.80. The trade was a 12.84% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders have sold 182,900 shares of company stock valued at $20,427,135. 24.30% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Apogee Therapeutics

Several large investors have recently bought and sold shares of APGE. Wellington Management Group LLP raised its stake in Apogee Therapeutics by 0.5% during the fourth quarter. Wellington Management Group LLP now owns 4,746,585 shares of the company’s stock valued at $358,272,000 after purchasing an additional 22,884 shares in the last quarter. Vanguard Group Inc. grew its stake in shares of Apogee Therapeutics by 27.3% in the 4th quarter. Vanguard Group Inc. now owns 2,857,824 shares of the company’s stock worth $215,709,000 after buying an additional 612,193 shares in the last quarter. T. Rowe Price Investment Management Inc. increased its holdings in shares of Apogee Therapeutics by 189,522.2% in the 4th quarter. T. Rowe Price Investment Management Inc. now owns 2,732,456 shares of the company’s stock worth $206,246,000 after buying an additional 2,731,015 shares during the last quarter. Janus Henderson Group PLC increased its holdings in shares of Apogee Therapeutics by 14.4% in the 1st quarter. Janus Henderson Group PLC now owns 2,360,596 shares of the company’s stock worth $198,809,000 after buying an additional 297,992 shares during the last quarter. Finally, Perceptive Advisors LLC raised its position in shares of Apogee Therapeutics by 72.4% during the 4th quarter. Perceptive Advisors LLC now owns 2,330,651 shares of the company’s stock valued at $175,918,000 after buying an additional 978,662 shares in the last quarter. Institutional investors own 79.04% of the company’s stock.

Apogee Therapeutics Trading Down 0.0%

NASDAQ:APGE opened at $132.68 on Friday. The stock has a 50-day moving average price of $88.55 and a 200 day moving average price of $79.67. The stock has a market capitalization of $8.21 billion, a P/E ratio of -30.64 and a beta of 0.62. Apogee Therapeutics has a 12-month low of $34.34 and a 12-month high of $133.16.

Apogee Therapeutics (NASDAQ:APGE) last posted its quarterly earnings results on Monday, May 11th. The company reported ($1.06) EPS for the quarter, topping analysts’ consensus estimates of ($1.07) by $0.01. On average, research analysts predict that Apogee Therapeutics will post -4.45 earnings per share for the current fiscal year.

About Apogee Therapeutics

Apogee Therapeutics, Inc is a clinical-stage biotechnology company dedicated to the discovery and development of novel small molecule therapeutics that selectively target the nuclear receptor RORγt, a master regulator of T cell-driven inflammatory pathways. By modulating RORγt activity, Apogee aims to offer an oral treatment option for patients with autoimmune and inflammatory skin disorders.

The company’s lead candidate, APG-157, is an oral RORγt inverse agonist currently undergoing early-stage clinical evaluation for moderate to severe plaque psoriasis.